Complexities of Gut Microbiome Dysbiosis in the Context of HIV Infection and Antiretroviral Therapy

Clinical Pharmacology and Therapeutics

Volumn 99, Issue 6, 2016, Pages 600-611

  Li, S X ^a   Armstrong, A J S ^a   Neff, C P ^a   Shaffer, M ^a,b   Lozupone, C A ^a   Palmer, B E ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL THERAPY; ARTICLE; DISEASE SEVERITY; DRUG TARGETING; DYSBIOSIS; GASTROINTESTINAL TRACT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTESTINE FLORA; NONHUMAN; PRIORITY JOURNAL; STAGING; VIRAL PHENOMENA AND FUNCTIONS; VIROME; ADVERSE EFFECTS; ANIMAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; IMMUNOLOGY; MICROBIOLOGY; MICROFLORA; PROCEDURES;

ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DYSBIOSIS; GASTROINTESTINAL MICROBIOME; HIV INFECTIONS; HUMANS; MICROBIOTA;

EID: 84963547172     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.363     Document Type: Article

References (73)

1. Paiardini, M., Muller-Trutwin, M. HIV-associated chronic immune activation. Immunol. Rev. 254, 78-101 (2013).
2. Nix, L.M., Tien, P.C. Metabolic syndrome, diabetes, and cardiovascular risk in HIV. Curr. HIV/AIDS Rep. 11, 271-278 (2014).
3. Aron-Wisnewsky, J., Clement, K. The gut microbiome, diet, and links to cardiometabolic and chronic disorders. Nat. Rev. Nephrol. 12, 160-181 (2015).
4. Kotler, D.P. HIV infection and the gastrointestinal tract. AIDS 19, 107-117 (2005).
5. Mehandru, S. et al. Primary HIV-1 infection is associated with preferential depletion of CD41 T lymphocytes from effector sites in the gastrointestinal tract. J. Exp. Med. 200, 761-770 (2004).
6. Mowat, A.M., Viney, J.L. The anatomical basis of intestinal immunity. Immunol. Rev. 156, 145-166 (1997).
7. Brenchley, J.M. et al. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood 112, 2826-2835 (2008).
8. Liang, S.C. et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J. Exp. Med. 203, 2271-2279 (2006).
9. Dillon, S.M. et al. HIV-1 infection of human intestinal lamina propria CD41 T cells in vitro is enhanced by exposure to commensal Escherichia coli. J. Immunol. 189, 885-896 (2012).
10. Jiao, Y. et al. The decrease of regulatory T cells correlates with excessive activation and apoptosis of CD81 T cells in HIV-1-infected typical progressors, but not in long-term non-progressors. Immunology 128, e366-375 (2009).
11. Allers, K. et al. Gut mucosal FOXP31 regulatory CD41 T cells and Nonregulatory CD41 T cells are differentially affected by simian immunodeficiency virus infection in rhesus macaques. J. Virol. 84, 3259-3269 (2010).
12. Moreno-Fernandez, M.E., Presicce, P., Chougnet, C.A. Homeostasis and function of regulatory T cells in HIV/SIV infection. J. Virol. 86, 10262-10269 (2012).
13. Deeks, S.G., Tracy, R., Douek, D.C. Systemic effects of inflammation on health during chronic HIV infection. Immunity 39, 633-645 (2013).
14. Round, J.L., Mazmanian, S.K. Inducible Foxp31 regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc. Natl. Acad. Sci. U. S. A. 107, 12204-12209 (2010).
15. Kato, L.M., Kawamoto, S., Maruya, M., Fagarasan, S. The role of the adaptive immune system in regulation of gut microbiota. Immunol. Rev. 260, 67-75 (2014).
16. Peterson, D.A., McNulty, N.P., Guruge, J.L., Gordon, J.I. IgA response to symbiotic bacteria as a mediator of gut homeostasis. Cell Host Microbe 2, 328-339 (2007).
17. Kawamoto, S. et al. Foxp3(1) T cells regulate immunoglobulin a selection and facilitate diversification of bacterial species responsible for immune homeostasis. Immunity 41, 152-165 (2014).
18. Ellis, C.L. et al. Molecular characterization of stool microbiota in HIVinfected subjects by panbacterial and order-level 16S ribosomal DNA (rDNA) quantification and correlations with immune activation. J. Acquir. Immune Defic. Syndr. 57, 363-370 (2011).
19. Gori, A. et al. Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the "COPA" pilot randomized trial. Mucosal Immunol. 4, 554-563 (2011).
20. Yu, G., Fadrosh, D., Ma, B., Ravel, J., Goedert, J.J. Anal microbiota profiles in HIV-positive and HIV-negative MSM. AIDS 28, 753-760 (2014).
21. Noguera-Julian, M. et al. Gut microbiota linked to sexual preference and HIV infection. eBioMedicine (2016).
22. Dillon, S.M. et al. An altered intestinal mucosal microbiome in HIV-1 infection is associated with mucosal and systemic immune activation and endotoxemia. Mucosal Immunol. 7, 983-994 (2014).
23. Lozupone, C.A. et al. Alterations in the gut microbiota associated with HIV-1 infection. Cell Host Microbe 14, 329-339 (2013).
24. Mutlu, E.A. et al. A compositional look at the human gastrointestinal microbiome and immune activation parameters in HIV infected subjects. PLoS Pathog. 10, e1003829 (2014).
25. Vazquez-Castellanos, J.F. et al. Altered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals. Mucosal Immunol. 8, 760-772 (2015).
26. Vujkovic-Cvijin, I. et al. Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci. Transl. Med. 5, 193ra91 (2013).
27. Nowak, P. et al. Gut microbiota diversity predicts immune status in HIV-1 infection. AIDS 29, 2409-2418 (2015).
28. Yatsunenko, T. et al. Human gut microbiome viewed across age and geography. Nature 486, 222-227 (2012).
29. De Cock, K.M. et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA 283, 1175-1182 (2000).
30. Glavan, T.W., Gaulke, C.A., Hirao, L.A., Sankaran-Walters, S., Dandekar, S. SIV-infection-driven changes of pattern recognition receptor expression in mesenteric lymph nodes and gut microbiota dysbiosis. J. Med. Primatol. 44, 241-252 (2015).
31. Klase, Z. et al. Dysbiotic bacteria translocate in progressive SIV infection. Mucosal Immunol. 8, 1009-1020 (2015).
32. Handley, S.A. et al. Pathogenic simian immunodeficiency virus infection is associated with expansion of the enteric virome. Cell 151, 253-266 (2012).
33. McKenna, P. et al. The macaque gut microbiome in health, lentiviral infection, and chronic enterocolitis. PLoS Pathog. 4, e20 (2008).
34. Yang, L. et al. HIV-induced immunosuppression is associated with colonization of the proximal gut by environmental bacteria. AIDS 30, 19-29 (2016).
35. Eckburg, P.B. et al. Diversity of the human intestinal microbial flora. Science 308, 1635-1638 (2005).
36. McHardy, I.H. et al. HIV infection is associated with compositional and functional shifts in the rectal mucosal microbiota. Microbiome 1, 26 (2013).
37. Dieffenbach, C.W., Fauci, A.S. Thirty years of HIV and AIDS: future challenges and opportunities. Ann. Intern. Med. 154, 766-771 (2011).
38. Kartalija, M., Sande, M.A. Diarrhea and AIDS in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 28, 701-705; quiz 6-7 (1999).
39. Montessori, V., Press, N., Harris, M., Akagi, L., Montaner, J.S. Adverse effects of antiretroviral therapy for HIV infection. CMAJ 170, 229-238 (2004).
40. Dinh, D.M. et al. Intestinal microbiota, microbial translocation, and systemic inflammation in chronic HIV infection. J. Infect. Dis. 211, 19-27 (2015).
41. Perez-Santiago, J. et al. Gut Lactobacillales are associated with higher CD4 and less microbial translocation during HIV infection. AIDS 27, 1921-1931 (2013).
42. Lozupone, C.A., Rhodes, M.E., Neff, C.P., Fontenot, A.P., Campbell, T.B., Palmer, B.E. HIV-induced alteration in gut microbiota: driving factors, consequences, and effects of antiretroviral therapy. Gut Microbes 5, 562-570 (2014).
43. Weingarden, A. et al. Dynamic changes in short-and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection. Microbiome 3, 10 (2015).
44. Willing, B.P. et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology 139, 1844-1854 e1 (2010).
45. Borg-von Zepelin, M. et al. HIV-protease inhibitors reduce cell adherence of Candida albicans strains by inhibition of yeast secreted aspartic proteases. J. Invest. Dermatol. 113, 747-751 (1999).
46. Perez-Matute, P., Perez-Martinez, L., Aguilera-Lizarraga, J., Blanco, J.R., Oteo, J.A. Maraviroc modifies gut microbiota composition in a mouse model of obesity: a plausible therapeutic option to prevent metabolic disorders in HIV-infected patients. Rev. Esp. Quimioter. 28, 200-206 (2015).
47. Iida, N. et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342, 967-970 (2013).
48. Clayton, T.A., Baker, D., Lindon, J.C., Everett, J.R., Nicholson, J.K. Pharmacometabonomic identification of a significant hostmicrobiome metabolic interaction affecting human drug metabolism. Proc. Natl. Acad. Sci. U. S. A. 106, 14728-14733 (2009).
49. Haiser, H.J., Gootenberg, D.B., Chatman, K., Sirasani, G., Balskus, E.P., Turnbaugh, P.J. Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science 341, 295-298 (2013).
50. Caceres, C.F., O'Reilly, K.R., Mayer, K.H., Baggaley, R. PrEP implementation: moving from trials to policy and practice. J. Int. AIDS Soc. 18, 20222 (2015).
51. Breitbart, M. et al. Genomic analysis of uncultured marine viral communities. Proc. Natl. Acad. Sci. U. S. A. 99, 14250-14255 (2002).
52. Norman, J.M. et al. Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell 160, 447-460 (2015).
53. Zhang, T. et al. RNA viral community in human feces: prevalence of plant pathogenic viruses. PLoS Biol. 4, e3 (2006).
54. Banyai, K. et al. Sequence heterogeneity among human picobirnaviruses detected in a gastroenteritis outbreak. Arch. Virol. 148, 2281-2291 (2003).
55. Holtz, L.R. et al. Geographic variation in the eukaryotic virome of human diarrhea. Virology 468-470, 556-564 (2014).
56. Li, S.K. et al. Detection and identification of plasma bacterial and viral elements in HIV/AIDS patients in comparison to healthy adults. Clin. Microbiol. Infect. 18, 1126-1133 (2012).
57. Foca, A., Liberto, M.C., Quirino, A., Marascio, N., Zicca, E., Pavia, G. Gut inflammation and immunity: what is the role of the human gut virome? Mediators Inflamm. 2015, 326032 (2015).
58. Cohen, C.R. et al. Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples. PLoS Med. 9, e1001251 (2012).
59. Schmid, G., Markowitz, L., Joesoef, R., Koumans, E. Bacterial vaginosis and HIV infection. Sex. Transm. Infect. 76, 3-4 (2000).
60. Brenchley, J.M. et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12, 1365-1371 (2006).
61. Sandler, N.G. et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J. Infect. Dis. 203, 780-790 (2011).
62. Vesterbacka, J. et al. Kinetics of microbial translocation markers in patients on efavirenz or lopinavir/r based antiretroviral therapy. PLoS One 8, e55038 (2013).
63. Srinivasa, S. et al. Plaque burden in HIV-infected patients is associated with serum intestinal microbiota-generated trimethylamine. AIDS 29, 443-452 (2015).
64. Haissman, J.M. et al. Microbiota-dependent marker TMAO is elevated in silent ischemia but is not associated with first-time myocardial infarction in HIV infection. J. Acquir. Immune Defic. Syndr. (2015).
65. d'Ettorre, G. et al. Probiotics reduce inflammation in antiretroviral treated, HIV-infected individuals: results of the "Probio-HIV" clinical trial. PLoS One 10, e0137200 (2015).
66. Falasca, K., Vecchiet, J., Ucciferri, C., Di Nicola, M., D'Angelo, C., Reale, M. Effect of probiotic supplement on cytokine levels in HIVinfected individuals: a preliminary study. Nutrients 7, 8335-8347 (2015).
67. Villar-Garcia, J. et al. Effect of probiotics (Saccharomyces boulardii) on microbial translocation and inflammation in HIV-treated patients: a double-blind, randomized, placebo-controlled trial. J. Acquir. Immune Defic. Syndr. 68, 256-263 (2015).
68. Crouzet, L., Rigottier-Gois, L., Serror, P. Potential use of probiotic and commensal bacteria as non-antibiotic strategies against vancomycinresistant enterococci. FEMS Microbiol. Lett. 362, 12 (2015).
69. Kristoff, J. et al. Early microbial translocation blockade reduces SIVmediated inflammation and viral replication. J. Clin. Invest. 124, 2802-2806 (2014).
70. Sandler, N.G. et al. Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, lowdensity lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection. J. Infect. Dis. 210, 1549-1554 (2014).
71. Klatt, N.R. et al. Probiotic/prebiotic supplementation of antiretrovirals improves gastrointestinal immunity in SIV-infected macaques. J. Clin. Invest. 123, 903-907 (2013).
72. Ortiz, A.M. et al. IL-21 and probiotic therapy improve Th17 frequencies, microbial translocation, and microbiome in ARV-treated, SIV-infected macaques. Mucosal Immunol. (2015).
73. Hofer, U. et al. Inadequate clearance of translocated bacterial products in HIV-infected humanized mice. PLoS Pathog. 6, e1000867 (2010).